StockData

Kura Oncology vs Arcus Biosciences

KURA and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KURA and RCUS compare

Arcus Biosciences is the larger company, worth 3.1 times as much as Kura Oncology ($2.1B against $666M).

Kura Oncology keeps more of each dollar of sales as profit, with a net margin of −369% compared with −393% at Arcus Biosciences.

Arcus Biosciences scores higher on the StockData Score (3 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKURARCUS
Size and price
Market cap$666M$2.1B
Share price$7.49$16.39
Change, 1 year−33.2%−18.3%
Change, 5 years−46.5%−64.6%
Beta (5Y)2.301.13
Employees260601
StockData Score
Total score13 (better)
Valuation score00
Growth score02 (better)
Performance score00
Health score11
Dividend score00
Valuation
P/S8.4× (better)17.8×
P/B37.1×4.5× (better)
FCF yield−13.4% (better)−22.8%
Fair value–$7.34
Margin of safety–−123%
Growth
Revenue growth (TTM)–−55.3%
Revenue growth, 5Y average–25.9%
Profitability
Operating margin−394% (better)−415%
Net margin−369% (better)−393%
FCF margin−112% (better)−406%
Return on equity−225%−90.8% (better)
Financial health
Debt / equity0.55–
Interest coverage−227.1×−44.2× (better)
Current ratio3.603.82 (better)
Altman Z-score−3.56−0.74 (better)
Piotroski F-score11
Dividends and buybacks
Buyback yield–−13.8%
Shareholder yield0.00% (better)−13.8%
Ownership
Held by institutions98.0%96.3%
Held by insiders2.7%31.7%
Insider net buying, 12 months$512K (better)−$9.3M
Short interest, % of float14.6%15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.